Diabetes is a chronic metabolic disorder that affects how the body regulates blood glucose. While most people associate the condition with long-term complications such as neuropathy, nephropathy, and cardiovascular disease, its effects on the immune system are equally significant—and often underestimated. The immune system in individuals with diabetes can be compromised, leading to a higher risk of infections and a suboptimal response to vaccinations. Understanding this interplay is critical for designing effective immunization strategies, especially as vaccine-preventable diseases continue to pose serious threats. This article explores the mechanisms behind diabetes-related immune dysfunction, reviews how common vaccines are affected, and offers evidence-based strategies to maximize vaccine protection for people living with diabetes.

How Diabetes Impairs Immune Function

The immune system relies on a complex network of cells, signaling molecules, and organs to detect and eliminate pathogens. In patients with diabetes, especially those with poorly controlled blood glucose, several key components of this network are disrupted. Chronic hyperglycemia directly impairs the function of neutrophils, macrophages, and T lymphocytes—cells that are essential for both innate and adaptive immunity. Neutrophils in hyperglycemic environments show reduced chemotaxis, decreased phagocytic activity, and diminished ability to produce reactive oxygen species, which are needed to kill bacteria and viruses. Similarly, macrophages become less efficient at antigen presentation, and T cells fail to proliferate and differentiate properly when blood sugar is elevated.

Beyond cellular dysfunction, diabetes also alters the cytokine milieu. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) are often chronically elevated, contributing to a state of low-grade inflammation that paradoxically blunts the acute inflammatory response needed to fight infections and respond to vaccines. Additionally, complement system activity is impaired, further reducing the body’s ability to clear pathogens and mount a robust vaccine-induced immune response. Glycemic variability—swings between high and low glucose—appears to be as harmful as sustained hyperglycemia, as it increases oxidative stress and damages immune cell membranes.

These immune deficits translate into higher infection rates. People with diabetes are at increased risk for influenza, pneumonia, skin infections, and even tuberculosis. They also tend to have more severe outcomes from infections such as COVID-19. Given that vaccines work by training the immune system to recognize specific antigens, any underlying immune dysfunction can diminish vaccine efficacy—a phenomenon that has been documented for multiple vaccines.

Impact of Diabetes on Vaccine Effectiveness

Numerous studies have shown that individuals with diabetes often produce weaker antibody responses after vaccination compared to their non-diabetic counterparts. The degree of impairment varies depending on the type of vaccine, the patient’s glycemic control, and other factors such as age, comorbidities, and body mass index. Below we review the evidence for several key vaccines.

Influenza Vaccine

Influenza is a particular concern for people with diabetes because they are more likely to develop complications such as pneumonia, hospitalization, and death. The influenza vaccine is recommended annually for all adults with diabetes, but its effectiveness may be reduced. Research published in the journal Diabetes Care found that diabetic patients had lower post-vaccination antibody titers to influenza A and B strains compared to healthy controls. Moreover, seroconversion rates—meaning the percentage of individuals who achieve a protective antibody level—were significantly lower in those with poorly controlled diabetes. To address this, the Centers for Disease Control and Prevention (CDC) now recommends that adults 65 and older, including those with diabetes, receive either a high-dose influenza vaccine (Fluzone High-Dose) or an adjuvanted influenza vaccine (Fluad) which generate stronger immune responses. Some studies also suggest that younger diabetic adults may benefit from these newer formulations, though official guidelines are still evolving.

External link: CDC: Vaccinations and Diabetes

Pneumococcal Vaccine

Pneumococcal disease—caused by Streptococcus pneumoniae—can lead to pneumonia, meningitis, and bacteremia. The Advisory Committee on Immunization Practices (ACIP) recommends that adults aged 19–64 with diabetes receive two pneumococcal vaccines: the 20-valent conjugate vaccine (PCV20) or PCV15 followed by the 23-valent polysaccharide vaccine (PPSV23) at least one year later. However, studies show that diabetic patients mount a weaker antibody response to pneumococcal polysaccharide antigens. For example, a 2019 study in Vaccine reported that diabetic adults had lower geometric mean antibody concentrations for multiple serotypes after PPSV23 vaccination compared to non-diabetic controls. The conjugate vaccine PCV13 (now PCV20) also induces a T-cell-dependent response, which may be relatively preserved but still suboptimal without adequate glycemic control.

External link: CDC: Pneumococcal Vaccine Recommendations

COVID-19 Vaccines

The COVID-19 pandemic highlighted the vulnerability of people with diabetes. Meta-analyses have demonstrated that diabetic patients are at 2–3 times higher risk of severe COVID-19 outcomes. In terms of vaccine response, studies show that while mRNA vaccines (e.g., Pfizer-BioNTech and Moderna) are effective, they elicit lower neutralizing antibody titers in individuals with diabetes, particularly those with poor glycemic control. One large study from Israel found that diabetic adults had higher rates of breakthrough infections compared to non-diabetic individuals, even after two doses of BNT162b2. Another study from the United Kingdom reported that antibody levels after the second dose declined faster in diabetic participants. As a result, health authorities in many countries recommend that immunocompromised individuals—including those with poorly controlled diabetes—receive additional (booster) doses and, in some cases, a third primary series dose.

Hepatitis B Vaccine

Hepatitis B virus infection is a serious risk for people with diabetes, especially those who use insulin or test blood glucose frequently with shared fingerstick devices. The CDC has recommended hepatitis B vaccination for all adults with diabetes aged 19–59, and for those 60 and older at the discretion of the clinician. However, the response to the hepatitis B vaccine is notoriously poor in diabetic patients. One study showed that only about 60–70% of diabetic adults mount a protective anti-HBs titer (≥10 mIU/mL) after the standard three-dose series, compared to >90% in healthy adults. Factors contributing to non-response include higher HbA1c levels, longer duration of diabetes, and presence of obesity. For those who do not respond, a second series of hepatitis B vaccine (with a 4-dose schedule) is recommended, and some experts suggest using the adjuvanted HEPLISAV-B vaccine which has shown higher seroprotection rates in diabetic and obese populations.

Other Vaccines

Limited but concerning evidence exists for other vaccines. For example, the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine may produce slightly lower antibody responses in adults with diabetes, although clinical protection remains adequate. Herpes zoster (shingles) vaccine—recommended for adults aged 50 and older and for those 19+ with immunocompromising conditions—appears to be effective in diabetic patients, but immune responses to the recombinant zoster vaccine (RZV) are blunted compared to healthy individuals, especially in older adults with long-standing diabetes. The World Health Organization also notes that diabetic response to yellow fever vaccine may be impaired, though data are sparse.

Mechanisms Behind Reduced Vaccine Response

The immune deficits observed in diabetes are not a simple consequence of high glucose. Several specific molecular pathways have been implicated. Advanced glycation end-products (AGEs) form when glucose reacts non-enzymatically with proteins and lipids. AGEs bind to receptors (RAGE) on immune cells, triggering chronic inflammation and inhibiting T-cell activation. Oxidative stress is also elevated in diabetes, damaging DNA and cell membranes of lymphocytes. The altered metabolism of fatty acids and glucose in immune cells leads to mitochondrial dysfunction, reducing the energy required for robust clonal expansion and antibody production. Additionally, the metabolic memory phenomenon means that past periods of poor glycemic control can leave lasting epigenetic changes in immune cells, impairing vaccine response even after glucose levels improve. This highlights the importance of long-term, rather than acute, glycemic management.

Furthermore, diabetes is often associated with other conditions—obesity, insulin resistance, hyperlipidemia, and hypertension—that independently suppress immune function. For instance, adipose tissue secretes pro-inflammatory cytokines that further impair vaccine-induced immunity. The immune system in diabetes is therefore a victim of multiple interacting insults.

Clinical Implications and Vaccination Strategies

Given the clear evidence of reduced vaccine effectiveness, clinicians must adopt proactive strategies to optimize protection for patients with diabetes. The following approaches are supported by current guidelines and research.

Optimize Glycemic Control Before Vaccination

While it may not always be possible to achieve perfect HbA1c before an appointment, scheduling vaccines when the patient’s diabetes is relatively stable can improve antibody responses. For elective vaccinations (e.g., hepatitis B series or booster doses), it is reasonable to aim for HbA1c <7.0% (or individualized targets) beforehand. Encouraging medication adherence, dietary compliance, and reducing glycemic variability in the weeks leading up to vaccination may help. Some evidence suggests that metformin itself has immunomodulatory effects that may improve vaccine responses, though more research is needed.

Use Higher-Dose or Adjuvanted Vaccines When Available

As noted earlier, high-dose influenza vaccine (Fluzone HD) and adjuvanted influenza vaccine (Fluad) are recommended for adults 65+ and can be considered for younger diabetic adults at increased risk of influenza complications. For hepatitis B, the adjuvanted vaccine HEPLISAV-B offers superior seroprotection in hard-to-immunize populations, including those with diabetes. For pneumococcal disease, using the conjugate vaccine PCV20 alone (which eliminates the need for a polysaccharide booster) simplifies the schedule and may improve overall response. In the COVID-19 setting, booster doses (mRNA bivalent or updated variants) are crucial to restore waning immunity in diabetic patients.

Consider Additional Booster Doses

The CDC and WHO now recommend an additional dose of the primary vaccine series for moderately to severely immunocompromised individuals. While diabetes alone is not classified as severe immunodeficiency in all guidelines, many experts advocate for an extra dose of hepatitis B vaccine if the patient does not seroconvert after the standard series. For influenza, a second dose in the same season is not recommended for adults, but high-dose options serve as an effective booster. For COVID-19, the initial series was two doses of mRNA; then a first booster, a bivalent booster, and now updated monovalent boosters (2024-2025 formulation) are recommended for all adults, with special emphasis on diabetic patients.

Check Antibody Titers When Appropriate

For hepatitis B, post-vaccination serologic testing (anti-HBs) 1–2 months after the final dose is recommended for patients with diabetes who are at high risk of needlestick injuries or who have ongoing exposure. If titers are <10 mIU/mL, revaccination with a second series (preferably adjuvanted vaccine) is indicated. For other vaccines, routine antibody testing is not generally recommended, but it may be considered in research or for patients with very poor glycemic control.

Coordinate Vaccination with Healthcare Team

Patients should inform their healthcare provider about their diabetes status before receiving any vaccine. The provider can review recent HbA1c values, check for hypoglycemia risks (since some vaccines may cause mild fever that affects glucose), and plan appropriate timing. Vaccination should be performed during a routine diabetes management visit when possible, ensuring that immunizations are not delayed due to temporary sick days or poorly controlled glucose. It is also advisable to have a sick-day management plan in place if the vaccine causes transient hyperglycemia or flu-like symptoms.

Managing Blood Sugar on the Day of Vaccination

While the vaccine itself does not directly raise blood glucose, the body’s immune response can cause temporary changes. Some individuals experience mild fever, muscle aches, or fatigue—symptoms that can mimic a mild illness and may increase stress hormones like cortisol, leading to elevated blood sugar. Conversely, loss of appetite or nausea from vaccine side effects could lead to hypoglycemia if medications (especially insulin or sulfonylureas) are not adjusted.

Patients are encouraged to:
- Monitor blood glucose more frequently on the day of and day after vaccination.
- Stay hydrated and eat small, balanced meals if appetite is reduced.
- Keep fast-acting glucose sources available (e.g., glucose tablets, juice) if they are prone to hypoglycemia.
- Contact their diabetes educator or physician if glucose levels become extreme (persistently >250 mg/dL or <70 mg/dL).

Optimal glucose control both before and after vaccination supports a stronger and more durable immune response. A study of influenza vaccine in older adults with diabetes found that those with HbA1c <7.0% had significantly higher antibody levels at 6 months post-vaccination compared to those with HbA1c >8.0%.

Conclusion

Diabetes exerts a profound influence on the immune system, leading to weakened responses to many routine vaccinations. This is not merely a theoretical concern—real-world data show higher infection rates and lower vaccine effectiveness for influenza, pneumococcus, hepatitis B, and COVID-19 in diabetic populations. However, proactive management can mitigate many of these effects. By optimizing glycemic control, selecting appropriate vaccine formulations, considering booster doses, and coordinating care with healthcare providers, patients with diabetes can achieve much stronger and more durable protection. The message is clear: vaccinations remain essential for people with diabetes, but they must be delivered with an understanding of the underlying immune deficits. Every patient deserves a personalized vaccination strategy that accounts for their diabetes status.

External link: American Diabetes Association: Vaccinations & Diabetes
External link: NIH: Diabetes and Vaccine Effectiveness (Review)